SecBot SecBot

NONOF

NOVO NORDISK A S
OTC· Pharmaceutical Preparations· CIK 0000353278 Biotech & Drug Discovery
$38.98 +0.05 (+0.13%)
Oct 27 4:00 PM ET · prev $38.93
Median target
$52.83
+36% · range $52.83–52.83
1 year
−24.6%
from $51.67 · Oct 28
30 days
+1.6%
from $38.38
52-week range
$35.03–63.20
−38% from high · low Apr 8
Avg volume 20D
107.1K
Oct 9 spike 425.3K
Short interest
11.40M
−6.3%
Days to cover
55.2
at average volume
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 5 reports · latest
Balance 0 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 5/5
Strongest BULLISH Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest −6.3% to 11.40M shares. 55.2 days to cover.

  • TrendDOWNTREND

    6% below its 50-day average.

The Street

12-month targets · 1 analysts

Price is below the lowest target. Median implies +36%.Targets as of Jul 8, 2026.

Washington

Corporate Lobbying

107 lobbying filings and 9 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Dec 23, 2014
FDA
SAXENDA

Short side

FINRA· Oct 15, 2026
11,403,378
shares short
-6.3%
vs prior settlement
55.2
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jun 8, 2026 SEC
Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion…
6-K — Impact 3/10
May 27, 2026 SEC
Novo Nordisk filed a 6-K to report ongoing share repurchase activity under a pre-announced program. Since 4 February…
6-K — Impact 3/10
May 22, 2026 SEC
Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing authorization for…
6-K — Impact 7/10
Dec 23, 2014 Event
SAXENDA

SecBot reports

6 filings · 1 bullish · 0 bearish · 5 neutral
All NONOF filing & press-release reports (6)